Home > Healthcare > Pharmaceuticals > Vaccines > Hepatitis B Vaccine Market

Hepatitis B Vaccine Market Size

Report ID: GMI5826
Published Date: May 2023
Report Format: PDF

Download Free Sample

Hepatitis B Vaccine Market Size

Hepatitis B Vaccine Market size accounted for USD 3.3 billion in 2022 and is estimated to grow at 5.1% to reach USD 5.7 billion by 2032. Growing prevalence of chronic infection, liver cirrhosis and liver cancer will positively influence the market growth.

To get key market trends

Download Free Sample

For instance, in 2019, according to the World Health Organization (WHO), 296 million people were living with chronic hepatitis B infection with 1.5 million new infection cases are registered each year. This indicates that there will huge number of patient pool infected with hepatitis B viral infection every year globally. The availability of effective preventive vaccines offering immunity against aforementioned diseases will offer unprecedented growth opportunities to the market.

Hepatitis B vaccine is a preventive vaccine that provides immunization against the hepatitis B virus (HBV). It is designed to stimulate the immune system to produce antibodies against the hepatitis B surface antigen (HBsAg), a protein found on the surface of the virus. The vaccine is typically administered through intramuscular injection and can be given as a single antigen vaccine or as a part of combination vaccines that protect against multiple diseases. It is recommended for infants, children, adolescents and adults that are at risk of HBV infection. It is also a routine part of immunization programs in many countries.

Hepatitis B Vaccine Market Report Attributes
Report Attribute	Details
Base Year:	2022
Hepatitis B Vaccine Market Size in 2022:	USD 3.3 Billion
Forecast Period:	2023 to 2032
Forecast Period 2023 to 2032 CAGR:	5.1%
2032 Value Projection:	USD 5.7 Billion
Historical Data for:	2018 to 2022
No. of Pages:	120
Tables, Charts & Figures:	203
Segments covered:	Type, End-use, and Region
Growth Drivers:	Rising prevalence of hepatitis B infection Increasing government initiatives and policies to promote vaccination Rising investments in R&D Increasing focus on preventive healthcare
Pitfalls & Challenges:	Stringent regulations for the approval of vaccine High cost of vaccine storage and transportation

Learn more about the key segments shaping this market

Download Free Sample

outine part of immunization programs in many countries.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for hepatitis B vaccine generated USD 3.3 billion in 2022 and is estimated to grow at 5.1% CAGR and amass USD 5.7 billion by 2032 driven by the high prevalence of chronic infection, liver cirrhosis, and liver cancer.

The combination vaccine segment accounted for over 65% market share in 2022 and is projected to witness robust growth over 2023-2032 owing to their increasing use to provide protection against multiple diseases in a single shot.

The North America hepatitis B vaccine industry held over 40.6% revenue share in 2022 and is set to grow at a considerable rate through 2032 attributed to the high prevalence of hepatitis B infections, coupled with the increasing population at risk, including newborns and healthcare workers.

The top firms operating in the hepatitis B vaccine industry are Merck & Co., Inc, Sanofi S.A., GlaxoSmithKline plc., and Dynavax Technologies Corporation, among others.